56361 20200221144306.0 doi 10.1093/infdis/jiv503 sideral 93909 ART-2016-93909 eng (orcid)0000-0001-7897-9173 Aguiló, N Universidad de Zaragoza Pulmonary but not subcutaneous vaccination confers protection to TB susceptible mice by an IL17-dependent mechanism. 2016 Access copy available to the general public Unrestricted Some of the most promising novel tuberculosis vaccine strategies currently under development are based on respiratory vaccination, mimicking the natural route of infection. In this work, we have compared pulmonary and subcutaneous delivery of BCG vaccine in the tuberculosis-susceptible DBA/2 mouse strain, a model in which parenterally administered BCG vaccine does not protect against tuberculosis. Our data show that intranasally but not subcutaneously administered BCG confers robust protection against pulmonary tuberculosis challenge. In addition, our results indicate that pulmonary vaccination triggers a Mycobacterium tuberculosis–specific mucosal immune response orchestrated by interleukin 17A (IL-17A). Thus, IL-17A neutralization in vivo reduces protection and abrogates M. tuberculosis–specific immunoglobulin A (IgA) secretion to respiratory airways and lung expression of polymeric immunoglobulin receptor induced following intranasal vaccination. Together, our results demonstrate that pulmonary delivery of BCG can overcome the lack of protection observed when BCG is given parenterally, suggesting that respiratory tuberculosis vaccines could have an advantage in tuberculosis-endemic countries, where intradermally administered BCG has inefficient effectiveness against pulmonary tuberculosis. info:eu-repo/grantAgreement/ES/MINECO/BIO2014-5258P This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No H2020 643381-TBVAC2020 info:eu-repo/grantAgreement/EC/H2020/643381/EU/TBVAC2020; Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development/TBVAC2020 info:eu-repo/semantics/openAccess All rights reserved http://www.europeana.eu/rights/rr-f/ 6.273 2016 IMMUNOLOGY 23 / 150 = 0.153 2016 Q1 T1 MICROBIOLOGY 15 / 124 = 0.121 2016 Q1 T1 INFECTIOUS DISEASES 7 / 84 = 0.083 2016 Q1 T1 3.931 2016 Infectious Diseases 2016 Q1 Immunology and Allergy 2016 Q1 info:eu-repo/semantics/article info:eu-repo/semantics/acceptedVersion (orcid)0000-0002-5748-6078 Álvarez-Arguedas, S Universidad de Zaragoza (orcid)0000-0001-7866-2803 Uranga, S Universidad de Zaragoza (orcid)0000-0001-8644-120X Marinova, D Universidad de Zaragoza (orcid)0000-0002-2787-9671 Monzón, M Universidad de Zaragoza (orcid)0000-0002-7173-7216 Badiola, J Universidad de Zaragoza (orcid)0000-0003-2993-5478 Martín, C Universidad de Zaragoza 1008 630 Universidad de Zaragoza Dpto. Microb.Med.Pr.,Sal.Públ. Área Microbiología 1003 443 Universidad de Zaragoza Dpto. Anatom.Histolog.Humanas Area Histología 1009 773 Universidad de Zaragoza Dpto. Patología Animal Área Sanidad Animal 1008 X Universidad de Zaragoza Dpto. Microb.Med.Pr.,Sal.Públ. Proy. investigación HQA 213, 5 (2016), 831-839 J. infect. dis. JOURNAL OF INFECTIOUS DISEASES 0022-1899 1642484 http://zaguan.unizar.es/record/56361/files/texto_completo.pdf Postprint 48552 http://zaguan.unizar.es/record/56361/files/texto_completo.jpg?subformat=icon icon Postprint oai:zaguan.unizar.es:56361 articulos driver 2020-02-21-13:34:46 ARTICLE